Phenyl hippurate is an organic compound, a derivative of hippuric acid, which is the main metabolite of benzoic acid in mammals. It is synthesized in the liver by conjugation of benzoic acid with glycine. Phenyl hippurate has been studied for its potential use as a diagnostic marker for liver function and as a therapeutic agent for various conditions such as gout and hyperuricemia. Research suggests that phenyl hippurate may have anti-inflammatory and antioxidant properties, which could contribute to its therapeutic effects. However, further research is needed to fully understand its pharmacological effects and potential benefits.'
| ID Source | ID |
|---|---|
| PubMed CID | 76323 |
| CHEMBL ID | 31331 |
| MeSH ID | M0106727 |
| Synonym |
|---|
| 2979-54-6 |
| glycine, n-benzoyl-, phenyl ester |
| phenyl hippurate |
| benzoylamino-acetic acid phenyl ester |
| CHEMBL31331 |
| phenylhippurate |
| DTXSID40877718 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID26046 | Michaelis constant for Actinidin-catalyzed hydrolysis | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Actinidin hydrolysis of substituted-phenyl hippurates: a quantitative structure-activity relationship and graphics comparison with hydrolysis by papain. |
| AID1149944 | Binding affinity to chymotrypsin (unknown origin) | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Quantitative structure-activity relationship of chymotrypsin-ligand interactions. |
| AID1149943 | Binding affinity to chymotrypsin (unknown origin) assessed as hydrolysis | 1977 | Journal of medicinal chemistry, Nov, Volume: 20, Issue:11 | Quantitative structure-activity relationship of chymotrypsin-ligand interactions. |
| AID26045 | Michaelis constant (Km), determined by Ficin hydrolysis at pH 6, 25 degrees Centigrade | 1984 | Journal of medicinal chemistry, Nov, Volume: 27, Issue:11 | Structure-activity relationship of the ficin hydrolysis of phenyl hippurates. Comparison with papain, actinidin, and bromelain. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||